insights_auto
Hvorfor er GNLX faldet med 4,40%?
Dyk dybere nedchevron_right
GNLX:NASDAQ
Genelux Corp
2,39 US$
arrow_downward
-4,40%(-0,11) 1D
21. okt., 13.12.46 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Ændring | Ændring i % |
|---|
insights_autoGenererer vigtig indsigt for GNLX...
Åbn
2,53 US$
Høj
2,57 US$
Lav
2,39 US$
Markedsværdi
108,14 mio.
Gns. vol.
257,05 t
Volumen
72,41 t
Højeste i 52 uger
8,54 US$
Laveste i 52 uger
2,29 US$
Indtægt pr. aktie
-0,87 US$
Beta
0,59
Aktier i omløb
45,24 mio.
Antal ansatte
26
Åbn
2,53 US$
Høj
2,57 US$
Lav
2,39 US$
Markedsværdi
108,14 mio.
Gns. vol.
257,05 t
Volumen
72,41 t
Højeste i 52 uger
8,54 US$
Laveste i 52 uger
2,29 US$
Indtægt pr. aktie
-0,87 US$
Beta
0,59
Aktier i omløb
45,24 mio.
Antal ansatte
26
Nyhedshistorier
Fra webkilder og nyhedspartnere
Traders Union
·
for 1 dag siden
Grant Cardone: 41 AI-relaterede virksomheder udgør 49 % af S&P 500-markedet
TradingView
·
for 1 time siden
TruGolf Holdings (NASDAQ: TRUG) Completes Polymath Acquisition, Offering Expansion into Institutional Tokenization
CNBC
·
for 58 minutter siden
Why the stock market’s fragile calm faces a major test starting Friday
Benzinga
·
for 8 minutter siden
12 Health Care Stocks Moving In Wednesday's Intraday Session
Profil
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Om Genelux Corp
Administrerende direktør-
Ansatte26
Grundlagt2001
HovedsædeWestlake Village, Californien, USA
Sektor-
Websitegenelux.com